Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
Kroon ED, Ungsedhapand C, Ruxrungtham K, Chuenyam M, Ubolyam S, Newell ME, van Leeuwen R, Kunanusont C, Buranapraditkul S, Sirivichayakul S, Lange JM, Cooper DA, Phanuphak P. Kroon ED, et al. Among authors: ubolyam s. AIDS. 2000 Jul 7;14(10):1349-56. doi: 10.1097/00002030-200007070-00007. AIDS. 2000. PMID: 10930149 Clinical Trial.
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, van Leeuwen R, Weverling GJ, Kunanusont C, Lange JM, Cooper DA, Phanuphak P. Ruxrungtham K, et al. Among authors: ubolyam s. AIDS. 2000 Jul 7;14(10):1375-82. doi: 10.1097/00002030-200007070-00010. AIDS. 2000. PMID: 10930152 Clinical Trial.
A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand.
Ruxrungtham K, Suwanagool S, Tavel JA, Chuenyam M, Kroon E, Ubolyam S, Buranapraditkun S, Techasathit W, Li Y, Emery S, Davey RT, Fosdick L, Kunanusont C, Lane HC, Phanuphak P; Vanguard Study Group. Ruxrungtham K, et al. Among authors: ubolyam s. AIDS. 2000 Nov 10;14(16):2509-13. doi: 10.1097/00002030-200011100-00013. AIDS. 2000. PMID: 11101062 Clinical Trial.
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, Ubolyam S, Buranapraditkun S, Tiengrim S, Pakker N, Kunanusont C, Lange JM, Cooper DA, Phanuphak P. Ungsedhapand C, et al. Among authors: ubolyam s. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):116-23. doi: 10.1097/00126334-200106010-00003. J Acquir Immune Defic Syndr. 2001. PMID: 11404532 Clinical Trial.
Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Rongkavilit C, van Heeswijk RP, Limpongsanurak S, Thaithumyanon P, Boonrod C, Hassink EA, Srigritsanapol A, Chuenyam T, Ubolyam S, Hoetelmans RM, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P. Rongkavilit C, et al. Among authors: ubolyam s. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):455-63. doi: 10.1097/00042560-200204150-00005. J Acquir Immune Defic Syndr. 2002. PMID: 11981361 Clinical Trial.
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial.
Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, Ruxrungtham K, Furrer H, Cooper D, Hirschel B, Bernasconi E, Cavassini M, Ebnöther C, Fagard C, Genné D, Khanna N, Perrin L, Phanupak P, Ubolyam S, Vernazza P, Yerly S; Swiss HIV Cohort Study. Ananworanich J, et al. Among authors: ubolyam s. AIDS. 2003 Oct 17;17(15):F33-7. doi: 10.1097/00002030-200310170-00001. AIDS. 2003. PMID: 14523294 Clinical Trial.
154 results